An Observational Study For Ambrisentan

This study is currently recruiting participants.

Verified by GlaxoSmithKline, August 2008

Sponsored by:	GlaxoSmithKline
Information provided by:	GlaxoSmithKline
ClinicalTrials.gov Identifier:	NCT00679224

Purpose

The purpose of the programme is to collect safety data on ambrisentan when used in clinical practice

Condition	Phase
Pulmonary Arterial Hypertension	Phase IV

MedlinePlus related topics: High Blood Pressure

Drug Information available for: Ambrisentan

Study Type:	Observational
Study Design:	Prospective
Official Title:	A Post-Marketing Observational Surveillance Programme for Ambrisentan (VOLT)

Further study details as provided by GlaxoSmithKline:

Estimated Enrollment:	800
Study Start Date:	June 2008

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

subjects who have been prescribed ambrisentan for a medically appropriate use (see approved product label)

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00679224

Sponsors and Collaborators

GlaxoSmithKline

Investigators

Study Director:

GSK Clinical Trials Call Centre, BM BCh DM MRCP MFPM

GlaxoSmithKline

More Information

Study ID Numbers:	110094
Study First Received:	May 14, 2008
Last Updated:	August 27, 2008
ClinicalTrials.gov Identifier:	NCT00679224
Health Authority:	European Union: European Medicines Agency

Keywords provided by GlaxoSmithKline:

observational safety

Study placed in the following topic categories:

Idiopathic pulmonary hypertension
Respiratory Tract Diseases
Hypertension, Pulmonary

Lung Diseases
Vascular Diseases
Hypertension

Additional relevant MeSH terms:

Cardiovascular Diseases

ClinicalTrials.gov processed this record on January 15, 2009